{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T10:28:50Z","timestamp":1758191330635,"version":"3.44.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04812-6","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T08:53:41Z","timestamp":1758099221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of plasma exchange on tirabrutinib plasma concentration in a patient with lymphoplasmacytic lymphoma: A case report"],"prefix":"10.1007","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9162-5405","authenticated-orcid":false,"given":"Takuya","family":"Araki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Kaneta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3341-5566","authenticated-orcid":false,"given":"Nobuhiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8982-2312","authenticated-orcid":false,"given":"Hideaki","family":"Yashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8754-345X","authenticated-orcid":false,"given":"Yuri","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1459-3970","authenticated-orcid":false,"given":"Yoshiyuki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3753-9862","authenticated-orcid":false,"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koujirou","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"4812_CR1","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40265-020-01318-8","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S (2020) Tirabrutinib: first approval. Drugs 80:835\u2013840. https:\/\/doi.org\/10.1007\/s40265-020-01318-8","journal-title":"Drugs"},{"key":"4812_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s12185-022-03514-6","volume":"117","author":"W Munakata","year":"2023","unstructured":"Munakata W, Ando K, Yokoyama M, Fukuhara N, Yamamoto K, Fukuhara S, Ohmachi K, Mishima Y, Ichikawa S, Ogiya D, Aoi A, Hatsumichi M, Tobinai K (2023) Long-term safety profile of tirabrutinib: final results of a Japanese phase I study in patients with relapsed or refractory B-cell malignancies. Int J Hematol 117:553\u2013562. https:\/\/doi.org\/10.1007\/s12185-022-03514-6","journal-title":"Int J Hematol"},{"issue":"3","key":"4812_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"W Rudi","year":"2014","unstructured":"Rudi W, Hendriks S, Yuvaraj LP, Kil (2014) Targeting bruton\u2019s tyrosine kinase in B cell malignancies. Nat Rev Cancer 14(3):219\u2013232. https:\/\/doi.org\/10.1038\/nrc3702","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"4812_CR4","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.3390\/ijms25147516","volume":"25","author":"M Shefali Mehra","year":"2024","unstructured":"Shefali Mehra M, Nicholls J Taylor (2024) The evolving role of bruton\u2019s tyrosine kinase inhibitors in B cell lymphomas. Int J Mol Sci 25(14):7516. https:\/\/doi.org\/10.3390\/ijms25147516","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4812_CR5","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/hematology.2020000118","volume":"2020","author":"A Lipsky","year":"2020","unstructured":"Lipsky A, Nicole Lamanna (2020) Managing toxicities of bruton\u2019s tyrosine kinase inhibitors. Hematol Am Soc Hematol Educ Program 2020(1):336\u2013345. https:\/\/doi.org\/10.1182\/hematology.2020000118","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"4812_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","volume":"23","author":"Y Narita","year":"2021","unstructured":"Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R (2021) Phase I\/II study of tirabrutinib, a second-generation bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma. Neuro Oncol 23:122\u2013133. https:\/\/doi.org\/10.1093\/neuonc\/noaa145","journal-title":"Neuro Oncol"},{"key":"4812_CR7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3389\/fonc.2020.00815","volume":"10","author":"S Allison Weaver","year":"2020","unstructured":"Allison Weaver S, Rubinstein, Robert F, Cornell (2020) Hyperviscosity syndrome in paraprotein-secreting conditions including Waldenstr\u00f6m macroglobulinemia. Front Oncol 10:815. https:\/\/doi.org\/10.3389\/fonc.2020.00815","journal-title":"Front Oncol"},{"issue":"9","key":"4812_CR8","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1182\/blood-2011-04-347690","volume":"119","author":"J Marvin","year":"2012","unstructured":"Marvin J, Stone, Steven A, Bogen (2012) Evidence-based focused review of management of hyperviscosity syndrome. Blood 119(9):2205\u20132208. https:\/\/doi.org\/10.1182\/blood-2011-04-347690","journal-title":"Blood"},{"issue":"2","key":"4812_CR9","first-page":"171","volume":"43","author":"F Marco Ballestri","year":"2007","unstructured":"Marco Ballestri F, Ferrari R, Magistroni M, Mariano GB, Ceccherelli G, Milanti M, De Palma A Albertazzi (2007) Plasma exchange in acute and chronic hyperviscosity syndrome: a rheological approach and guidelines study. Ann Ist Super Sanit\u00e0 43(2):171\u2013175","journal-title":"Ann Ist Super Sanit\u00e0"},{"issue":"2","key":"4812_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/cpt.2439","volume":"111","author":"A Meng","year":"2022","unstructured":"Meng A, Humeniuk R, J\u00fcrgensmeier JM, Hsueh C-H, Matzkies F, Grant E, Truong H, Billin AN, Yu H, Feng J, Kwan E, Tarnowski T, Cara H, Nelson (2022) Semi- mechanistic PK\/PD modeling and simulation of irreversible BTK Inhibition to support dose selection of tirabrutinib in subjects with RA. Clin Pharmacol Ther 111(2):416\u2013424. https:\/\/doi.org\/10.1002\/cpt.2439","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"4812_CR11","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1592\/phco.27.11.1529","volume":"27","author":"B Rami","year":"2007","unstructured":"Rami B, Ibrahim C, Liu, Simon M, Cronin BC, Murphy R, Cha P, Swerdlow DJ, Edwards (2007) Drug removal by plasmapheresis: an evidence-based review. Pharmacotherapy 27(11):1529\u20131549. https:\/\/doi.org\/10.1592\/phco.27.11.1529","journal-title":"Pharmacotherapy"},{"issue":"1","key":"4812_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13054-024-05077-w","volume":"28","author":"E Ugur Balaban","year":"2024","unstructured":"Ugur Balaban E, Kara EK, Kaya OI, Ozcebe M, Akova A, Topeli K, Yorganci K, Demirkan (2024) Effect of therapeutic plasma exchange on antimicrobials in critically ill patients. Crit Care 28(1):280. https:\/\/doi.org\/10.1186\/s13054-024-05077-w","journal-title":"Crit Care"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04812-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04812-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04812-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T08:53:41Z","timestamp":1758099221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04812-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4812"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04812-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This case report was conducted in accordance with the institutional policy, and written informed consent was obtained from the patient for publication of this case. The report was prepared in accordance with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\u00a0<!--Emphasis Type='Bold' removed-->and consent to publish"}}],"article-number":"88"}}